Matinas BioPharma
MTNB
49 hedge funds and large institutions have $21.5M invested in Matinas BioPharma in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 11 closing their positions.
199% more capital inflows, than outflows
Capital inflows: $2.25M | Capital outflows: $750K
0.91% more ownership
Funds ownership: 11.62% → 12.53% (+0.91%)
11% less funds holding
Funds holding: 55 → 49 (-6)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neville Rodie & Shaw
New York
|
+$1.32M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$404K |
| 3 |
Sargent Investment Group
Bethesda,
Maryland
|
+$241K |
| 4 |
Jane Street
New York
|
+$112K |
| 5 |
Virtu Financial
New York
|
+$70.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Courage Capital Management
Nashville,
Tennessee
|
-$509K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$60.6K |
| 3 |
Sandhill Capital Partners
Buffalo,
New York
|
-$40K |
| 4 |
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$26K |
| 5 |
Integrated Wealth Concepts
Waltham,
Massachusetts
|
-$20K |
MTNB Hedge Fund Activity: Q2 2022 in Review
49 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2022, worth a combined $21.5M — up 6% from $20.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of MTNB and 5 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was Neville Rodie & Shaw, adding an estimated $1.32M. The largest seller was Courage Capital Management, cutting an estimated $509K.
- 49 institutional investors held Matinas BioPharma (MTNB) as of Q2 2022, down from 55 in Q1 2022.
- Funds reported $21.5M of Matinas BioPharma stock for Q2 2022, up 6% quarter-over-quarter.
- 5 funds opened new Matinas BioPharma positions in Q2 2022 and 11 closed out, a net change of -6 holders.
- The largest Matinas BioPharma buyer in Q2 2022 was Neville Rodie & Shaw, an estimated $1.32M added.
- The largest Matinas BioPharma seller in Q2 2022 was Courage Capital Management, an estimated $509K sold.
Based on aggregated 13F filings for Q2 2022.